News
-
ELEVATING AWARENESS | 29 February Is Rare Disease Day
Rare Disease Day is the globally-coordinated movement on rare diseases, working towards equity in social opportunity, healthcare, and access to diagnosis and therapies for people living with a rare disease.…
Read More » -
PAROXYSMAL NOCTURNAL HEMOGLOBINURIA | Ruxoprubart Scores FDA Orphan Drug Designation for PNH Treatment
FDA’s recognition of Ruxoprubart as an orphan drug for PNH underscores its potential to fulfill a crucial need for individuals grappling with this disease condition. Ruxoprubart is currently undergoing a…
Read More » -
BREAKING NEWS | TIF’s Collaboration with WHO Extended to 2027
Our enduring collaboration was newly endorsed by WHO’s Executive Board at its 154th session in January 2024, demonstrating our significant and ongoing contribution to WHO’s strategic health objectives. This extension…
Read More » -
APLASTIC ANEMIA | Incidence and Clinical Management in Spain Consistent with Other Studies
The study was carried out through a multicenter, ambispective, observational approach encompassing 7 Spanish hospitals, catering to roughly 3.91 million individuals, over the span from 2010 to 2019. The research…
Read More » -
ADVOCACY IN ACTION | Highlights from the TIF Meeting with Greek Health Minister, Adonis Georgiadis
A productive meeting between the Greek Minister of Health, Mr. Adonis Georgiades, and a Thalassaemia International Federation (TIF) delegation took place on February 7, 2024. The discussions centered on longstanding…
Read More » -
-
NEW WAVE OF LEADERSHIP | WHO Appoints Regional Directors for Eastern Mediterranean, South-East Asia, and Western Pacific Regions
These influential professionals were selected by Regional Committees and confirmed by the Executive Board. Beginning their roles on 1st February 2024, Dr. Hanan Hassan Balkhy will take charge as Regional…
Read More » -
MYELODYSPLASTIC SYNDROMES | Advantages of Iron Chelation Revealed in Analysis of Low-Risk MDS
A recent groundbreaking study sheds new light on the effectiveness of iron chelation therapy (ICT) for patients suffering from low-risk myelodysplastic syndromes (LR-MDS). By delving into the impact of ICT…
Read More » -
BREAKING | Vertex and CRISPR’s Gene-editing Therapy Casgevy Receives Early FDA Approval for β-Thalassaemia Treatment
Just one month prior, Casgevy made history as the first CRISPR gene editing therapy to enter the US market when it was approved for sickle cell disease. Now, the FDA…
Read More » -
EXCLUSIVE WEBINAR | Guidelines for the Management of Non-Transfusion Dependent β-Thalassaemia
📌 Webinar Title: Guidelines for the Management of Non-Transfusion Dependent β-Thalassaemia 📌 Date & Time: Friday, February 02, 2024, 15:00 CET Recognizing the Clinical Relevance of NTDT Non‐transfusion‐dependent thalassaemias…
Read More »